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RESPOND is a prospective, single-arm study enrolling 1014 transcatheter aortic valve replacement (TAVR) patients. +e
objective of this analysis is to assess the impact of cerebral embolic protection (CEP) devices and prosthetic valve repositioning
on the risk of neurologic complications in patients treated with the fully repositionable Lotus Valve in the RESPOND
postmarket study. Valve repositioning and CEP use were at the operators’ discretion. Stroke events were adjudicated by an
independent medical reviewer. +is analysis assessed the baseline differences among patients according to CEP use and valve
repositioning and evaluated the neurological complications at 72 hours after TAVR, hospital discharge, and 30-day follow-up.
A multivariate analysis was performed to identify the potential predictors of stroke. Of the 996 patients implanted with the
Lotus Valve (mean age: 80.8 years, 50.8% female, STS score 6.0± 6.9), 92 cases (9.2%) used CEP.+e overall rate of acute stroke/
transient ischemic attack (TIA) was 3.0% at 72 hours after TAVR. +e 72-hour stroke/TIA rate was 1.1% in patients who had
CEP and 3.2% in those who did not. Use of CEP was associated with a 2.1% absolute reduction in the risk of acute neurological
events (relative risk reduction: 65.6%), although the difference was not statistically significant (p � 0.51). Repositioning of the
Lotus Valve occurred in 313/996 procedures (31.4%). +e 72-hour rate of stroke/TIA was similar in patients who had valve
repositioning (2.9%) compared with those who did not (3.1%; p � 0.86). +e selective use of a CEP device in the RESPOND
study was associated with a nonsignificantly lower risk for stroke within 72 hours. +e use of the repositioning feature of the
Lotus Valve did not increase the stroke risk.
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1. Introduction
Transcatheter aortic valve replacement (TAVR) is the pre-
ferred treatment for many patients with aortic stenosis at
increased surgical risk. However, neurologic complications
remain a concern, particularly with regard to repositioning
of the prosthetic valve during the procedure, which has been
associated with early stroke [1, 2]. To mitigate this risk,
transcatheter filters have been used to capture debris
embolized during the TAVR procedure [3–5]. In the ran-
domized SENTINEL trial, use of a double-filter cerebral
embolic protection (CEP) device was associated with a trend
towards a lower periprocedural stroke rate within 72 hours
compared with patients undergoing unprotected TAVR [3].
Likewise, a large patient-level meta-analysis of CEP use in
TAVR patients showed a significant reduction of peri-
procedural stroke and the composite of periprocedural
mortality and stroke in patients in whom a double-filter CEP
device was used [6].
Here, we evaluate the impact of selective use of an
embolic protection device and of repositioning of the
mechanically-expanded Lotus Valve in the RESPOND
study, a large “all-comers” postmarket registry.
2. Methods
+e RESPOND (Repositionable Lotus Valve System–Post-
Market Evaluation of Real World Clinical Outcomes) study
is a prospective, open-label, postmarket registry that en-
rolled 1014 patients with symptomatic aortic stenosis and
elevated surgical risk at 41 centers in Europe, New Zealand,
and Latin America [7].
+e protocol was approved by the locally-appointed
institutional review boards/ethics committees; the study was
conducted in accordance with the International Conference
on Harmonization Guidelines for Good Clinical Practice
and the ethical principles outlined in the Declaration of
Helsinki. All patients gave written informed consent. +e
study was sponsored by Boston Scientific Corporation and
registered with ClinicalTrials.gov (NCT#02031302).+e data
and study protocol for this clinical trial may be made
available to other researchers in accordance with Boston
Scientific’s Data Sharing Policy (http://www.
bostonscientific.com/en-US/data-sharing-requests.html).
+e Lotus Valve (Boston Scientific Corporation, Marl-
borough, MA) is a bioprosthetic aortic valve comprised of a
braided nitinol wire frame with three bovine pericardial
leaflets premounted on a preshaped delivery catheter and
deployed via controlled mechanical expansion [8–10]. +e
Lotus Valve functions early in the deployment process, and
rapid pacing is not required. A polymer membrane sur-
rounding the lower half of the Lotus Valve was designed to
reduce paravalvular regurgitation by filling the space be-
tween the native annulus and the prosthetic valve frame.
Repositioning or retrieval of the valve is possible at any point
prior to uncoupling and release. RESPOND evaluated the
Lotus Valve sizes of 23mm, 25mm, and 27mm, for im-
plantation in native annulus sizes ≥20mm to ≤27mm.
+e use of a CEP device in conjunction with the Lotus
Valve was at the operators’ discretion (i.e., selective use). All
cases used the dual-filter Sentinel system (Claret Medical, a
subsidiary of Boston Scientific Corporation, Marlborough,
MA). Device specifics and mode of operations have been
described elsewhere [11]. In brief, the device consists of
proximal and distal nitinol filters with 140 μm pores,
deployed with a dedicated delivery catheter into the bra-
chiocephalic trunk and the left common carotid,
respectively.
+e primary endpoint of RESPOND was all-cause
mortality at 30 days and 1 year after procedure [7, 12].
Additional Valve Academic Research Consortium (VARC)-
2 efficacy and safety outcomes [13] were evaluated, with all
study end point-related clinical events (i.e., all-cause mor-
tality and stroke events) reported by study investigators
assessed by an independent medical reviewer (IMR). As per
VARC-2 criteria, a stroke was defined as an acute episode of
focal or global neurological dysfunction caused by brain,
spinal cord, or retinal vascular injury as a result of hem-
orrhage or infarction; a transient episode of focal neuro-
logical dysfunction lasting <24 hours caused by brain, spinal
cord, or retinal ischemia, without acute infarction, was
considered a transient ischemic attack (TIA). +e RE-
SPOND study protocol did not require confirmation of TIA
by MRI or neurologist evaluation. +is analysis of RE-
SPOND focuses on acute neurologic events (stroke and TIA)
occurring within 30 days of TAVR.
Baseline and procedural characteristics were compared
for patients with and without CEP use and valve reposi-
tioning; 2-sided p values were derived from a chi-squared or
Fisher’s exact test for categorical variables. A multivariate
regression analysis evaluated clinical, anatomic, electro-
cardiographic, and procedural characteristics as potential
predictors of stroke; these factors were assessed by logistic
regression with Wald’s chi-squared test and expressed as
odds ratios with 95% confidence intervals. Significance was
defined as p< 0.05. No imputation of missing data was
performed. Statistical analysis was performed using SAS
software, version 9.2 or more (SAS Institute, Cary, North
Carolina).
3. Results
+e RESPOND study enrolled 1014 patients between May
2014 and February 2016; 996 patients were implanted with a
Lotus Valve (mean age: 80.8 years, 50.8% female, STS score
6.0± 6.9). A cerebral embolic protection device was used in
92 patients (9.2%).+e patients in whomCEP was used were
significantly more likely to have a history of congestive heart
failure (59.8% vs. 35.5%; p< 0.001) and prior MI (26.1% vs.
14.8%; p< 0.01) (Table 1). Additionally, porcelain aorta
(8.7% vs. 3.9%; p � 0.05) and severe aortic valve calcification
(50.0% vs. 32.2%; p< 0.001) were more common in patients
with CEP. Repositioning of the valve occurred in 31.4% of
procedures (n� 313/996), with a similar frequency in pa-
tients with (33.7%; 31/92 patients) and without (31.2%; 282/
904 patients) CEP use. Overall, baseline characteristics were
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comparable among patients with and without repositioning
(Table 1).
+e overall rate of post-TAVR acute neurological
complications (i.e., stroke/TIA) was 3.0% at 72 hours and
3.9% through 30 days (Table 2). Patients in whom CEP was
used had a numerically lower rate of neurological events at
all the time points, although the difference did not reach the
statistical significance. +e use of CEP was associated with a
2.1% absolute reduction in the risk of neurological events
within 72 hours (relative risk reduction: 65.6%; p � 0.51)
and a 1.9% absolute reduction in the 30-day risk of stroke/
TIA (relative risk reduction: 46.3%; p � 0.57); however,
these reductions were not statistically significant. Valve
repositioning did not affect the stroke rate at any time point
(Table 2). +e rate of stroke within 72 hours was not sig-
nificantly different in patients with and without reposi-
tioning regardless of whether CEP was also used (Table 3).
A univariate analysis was performed to identify potential
patient or procedural factors associated with acute stroke/
TIA (≤72 hours after procedure) (Supplementary Table 1).
Multivariate modeling revealed that patients with a history
of congestive heart failure were less likely to experience a
stroke (odds ratio [95% CI]: 0.30 [0.11, 0.82]; p � 0.02);
however, the analysis did not identify any other factors that
significantly predicted the stroke/TIA through 72 hours
(Figure 1). A similar analysis for stroke/TIA at hospital
discharge also did not identify any predictive factors (data
not shown).
4. Discussion
Here, we present data from the multicenter, international
RESPOND study, the largest study to date using the
mechanically-expanded Lotus Valve in routine clinical
practice. +e study represents a selective use of dual-filter
cerebral embolic protection, in 9.2% of patients. A 2.1%
absolute reduction in the risk of periprocedural stroke was
observed, corresponding to a two-thirds reduction in rela-
tive risk.+is sizable numerical difference, however, failed to
reach statistical significance due to a relatively small pop-
ulation of patients in which CEP was used. Repositioning of
the prosthetic valve, which occurred in approximately one in
three patients, was not associated with an increased risk of
neurological events.
Although the reduction in stroke risk observed in
RESPOND was not statistically significant, it is in con-
cordance with the clinical results of other contemporary
randomized trials and propensity score-matched analyses
(Figure 2). +e SENTINEL trial included 363 patients with
a 2 : 1 randomization for CEP versus no CEP [3]. Within
72 hours, there was a strong trend towards stroke re-
duction with CEP compared with unprotected TAVR
procedures (3.0% versus 8.2%, respectively; p � 0.05) [14].
Likewise, in a large propensity score-matched population
including 560 patients, use of an embolic protection
device resulted in a significant reduction in stroke at 48
hours (1.1% vs. 3.6%; p � 0.03), as well as within 7 days
(1.4% vs. 4.6%; p � 0.03) [15].
Although a recent meta-analysis of 16 TAVR studies
performed with and without CEP could not confirm or
exclude a difference in clinically-evident stroke (relative risk:
0.70; 95% CI: 0.38–1.29; p � 0.26) [16], a large patient-level
meta-analysis combining data from 1306 patients drawn
from the SENTINEL US IDE trial [3], CLEAN-TAVI study
[4], and a large registry by Seeger et al. reconfirms the
protective effect of use of CEP in TAVR patients [6]. +e
primary endpoint of the analysis was procedural stroke
within 72 hours after TAVR according to VARC-2 criteria.
Table 1: Baseline characteristics in the RESPOND patient population, according to cerebral embolic protection use and valve repositioning.
Baseline characteristic
Embolic protection use Valve repositioning
No CEP CEP
p value No REPOS. REPOS. p valueN� 904 N� 92 N� 683 N� 313
Age (years) 80.9± 6.5 80.0± 6.4 0.24 80.9± 6.3 80.5± 7.0 0.39
Gender (female) 49.9% 59.8% 0.07 52.0% 48.2% 0.27
BMI (kg/m2) 27.3± 5.6 27.1± 5.0 0.84 27.4± 5.7 26.9± 5.1 0.22
STS score (%) 6.0± 7.0 5.8± 5.8 0.89 5.6± 6.0 6.8± 8.6 0.02
EuroSCORE 2011 (%) 8.1± 8.4 7.1± 8.2 0.28 8.0± 8.2 8.0± 8.8 0.98
Diabetes, medically treated 22.3% 23.1% 0.87 22.7% 21.7% 0.73
History of hyperlipidemia 54.4% 57.8% 0.54 54.5% 55.2% 0.82
History of hypertension 78.4% 86.8% 0.06 79.5% 78.5% 0.72
Porcelain aorta 3.9% 8.7% 0.05 4.4% 4.2% 0.86
Aortic valve calcification, severe (site-reported) 3.2.% 50.0% <0.001 32.7% 36.4% 0.24
Hostile chest 0.8% 3.3% 0.06 0.9% 1.3% 0.52
History of cerebrovascular accident 9.2% 12.0% 0.39 8.5% 11.5% 0.13
History of coronary artery disease 55.9% 57.6% 0.76 56.7% 54.8% 0.58
History of congestive heart failure 35.5% 59.8% <0.001 36.3% 40.8% 0.17
History of atrial fibrillation 34.5% 27.8% 0.20 34.5% 32.6% 0.55
Prior MI 14.8% 26.1% <0.01 15.3% 17.2% 0.46
Prior PCI 29.5% 33.0% 0.49 29.6% 30.3% 0.81
Prior CABG 11.7% 18.5% 0.06 11.1% 15.0% 0.08
Prior pacemaker 13.7% 8.7% 0.18 13.3% 13.1% 0.92
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+e secondary endpoint was the combination of all-cause
mortality or all-stroke within 72 hours after TAVR. In the
propensity-matched population, which consisted of 533
patients treated with TAVR without CEP and 533 patients
treated with TAVR with CEP, patients were similar with
respect to baseline characteristics, procedural approach, and
valve type. In patients undergoing TAVR with dual-filter
CEP, procedural all-stroke was significantly lower compared
with unprotected procedures (1.88% vs. 5.44%; odds ratio
[95% CI]: 0.35 [0.17–0.72]; relative risk reduction: 65%;
p � 0.003). In addition, all-cause mortality and all-stroke
were significantly lower (2.06% vs 6.00%; odds ratio [95% CI]:
0.34 [0.17–0.68]; relative risk reduction: 66%; p � 0.001).
Imaging studies have increased the awareness of sub-
clinical (silent) ischemic events occurring in TAVR patients,
although the clinical impact of such events on cognitive
function is unclear [17, 18]. +e Neuro-TAVI study was a
prospective, multicenter observational study designed to
evaluate neurologic injury, cerebral ischemic lesion for-
mation, and cognitive changes after TAVR [19]. +e rate of
disabling stroke at hospital discharge was 2.3%, similar to
that observed in RESPOND. However, the study found that
Table 2: Neurological complications through 30 days after TAVR in patients with and without CEP use and valve repositioning.
Post-TAVR neurological complications
Overall
population
Embolic protection use Valve repositioning
No CEP CEP
p value No REPOS. REPOS. p valueN� 996 N� 904 N� 92 N� 683 N� 313≤72 hr
Stroke/TIA 3.0% (30) 3.2% (29) 1.1% (1) 0.51 3.1% (21) 2.9% (9) 0.86
Stroke 2.5% (25) 2.7% (24) 1.1% (1) 0.72 2.5% (17) 2.6% (8) 0.95
Disabling stroke 1.8% (18) 2.0% (18) 0.0% (0) 0.40 1.6% (11) 2.2% (7) 0.49
Discharge
Stroke/TIA 3.7% (37) 3.9% (35) 2.2% (2) 0.57 3.8% (26) 3.5% (11) 0.82
Stroke 3.1% (31) 3.3% (30) 1.1% (1) 0.35 3.1% (21) 3.2% (10) 0.92
Disabling stroke 2.2% (22) 2.4% (22) 0.0% (0) 0.25 1.9% (13) 2.9% (9) 0.33
30-days
Stroke/TIA 3.9% (39) 4.1% (37) 2.2% (2) 0.57 3.8% (26) 4.2% (13) 0.79
Stroke 3.2% (32) 3.4% (31) 1.1% (1) 0.35 3.1% (21) 3.5% (11) 0.71
Disabling stroke 2.3% (23) 2.5% (23) 0.0% (0) 0.26 1.9% (13) 3.2% (10) 0.21
Table 3: Effect of valve repositioning and cerebral embolic protection use on acute stroke.
Stroke ≤72 hr after TAVR Valve repositioning No repositioning p valueN� 313 N� 683
With CEP n� 31 n� 61 1.00All-stroke 0.0% (0) 1.7% (1)
No CEP n� 282 n� 622 0.81All-stroke 2.8% (8) 2.6% (16)
0.30
History of congestive heart failure
History of hypertension
Prior carotid endarterectomy/ 
carotid artery stenting
Parameter
0.46
3.95
p = 0.076
p = 0.067
p = 0.019
1 2 3 4 50
Odds Ratio
Figure 1: Multivariate regression analysis to evaluate potential predictors of acute stroke/TIA. Patients with a history of congestive heart
failure were less likely to experience a stroke; however, multivariate modeling did not identify any additional factors that significantly
predicted stroke/TIA through 72 hours.
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1 in 5 patients exhibited clinically evident neurological
impairment accompanied by imaging evidence of cerebral
ischemia at discharge and that the effect was persistent, with
40% of patients exhibiting reduced cognitive measures 30
days after procedure.+ere is some evidence that use of CEP
may help to mitigate the impact of subclinical ischemic
events. An early randomized controlled trial of the Claret
dual-filter device (MISTRAL-C) enrolling 65 TAVR patients
found neurocognitive deterioration was present in 4% of
patients with protection versus 27% of control patients
(p � 0.017) at 30 days [5].
In this study, patients in whom CEP was used were
more likely to have highly calcified aorta or aortic valve
leaflets and thus had the potential for an increased risk of
stroke related to dislodgement of debris during the
procedure. Nevertheless, the rate of cerebral ischemic
events was lower in this high-risk population with CEP
compared with patients undergoing TAVR without ce-
rebral protection. Calcification was not a significant
predictor of stroke nor was the repositioning of the Lotus
Valve associated with an increased risk of neurological
events. Other studies of patients treated with the Lotus
Valve have likewise shown that repositioning is not as-
sociated with an increased risk of major adverse cardio-
vascular or cerebrovascular events within 30 days [20, 21].
A comparative histopathological and histomorphometric
analyses of captured debris by a double-filter embolic
protection device demonstrated the total area of captured
debris and the particle size captured varied depending on
the type of TAVR device used (i.e., self-expanding vs.
balloon-expandable vs. mechanically expanded) [22];
particles measuring larger than 1mm were captured
significantly more often with the balloon-expandable
valve, while particle size was lowest with the mechan-
ically-expanded Lotus Valve. Our findings support the use
of the repositioning feature of the Lotus Valve without an
increase in the risk of acute neurological complications.
Of note, our multivariate analysis in this large patient
population did not identify an individual predictor for
neurological events. It is challenging to predict the risk of
stroke in a single patient undergoing TAVR, as there are
several potential contributing factors which may be as-
sociated with the occurrence of stroke, including age,
calcification of the valve and/or left ventricular outflow
tract, atrial fibrillation, and presence of aortal plaques or
calcification. Additionally, as the use of CEP in the study
was at the operators’ discretion (i.e., not randomized),
there is the potential for bias related to patient selection.
+e results of the multivariate analysis should thus be
interpreted with care and be considered to be hypothesis-
generating.
+is analysis has several other limitations. RESPOND is
not a randomized study and thus lacks a direct comparator.
+e use of CEP in RESPONDwas approximately 10%, which
represents selective use of an embolic protection device in
routine clinical practice, but nonetheless limits the sample
size for analyses. Given the limited sample size and low
overall incidence of stroke in the study, the multivariate
analysis was underpowered and there were no observable
trends related to potential predictors of stroke. Similarly, the
No CEP use
CEP use
Acute stroke rate post-TAVIDual-filterCEP device 
RESPOND
postmarket study7
72hr
SENTINEL
randomized Trial14
72hr
Seeger et al.
propensity-matched15
48hr
p = 0.03
p = 0.05
p = 0.72
P < 0.01
Seeger et al.
meta-analysis6
72hr
n = 234
n = 111
n = 280
n = 280
n = 533
n = 533
n = 92
n = 904 2.7%
5.4%
8.2%
3.6%
1.1%
1.9%
3.0%
1.1%
Figure 2: Comparative reduction in stroke risk with cerebral embolic protection. Use of a dual-filter cerebral embolic protection (CEP)
device during transcatheter aortic valve replacement was associated with a numerical reduction in acute stroke in RESPOND, which is in
concordance with that observed in other clinical analyses. 15Seeger et al., JACC: Cardiovascular Interventions, 10, 2297–2303, 2017. 14Data
presented at SENTINEL CPS FDA Advisory Panel, February 23, 2017; accessed at https://www.fda.gov/media/103414/download. 6Seeger et
al., European Heart Journal, 40, 1334–1340, 2019. 7Falk et al., European Heart Journal, 38, 3359–3366, 2017.
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sample size is too small to determine if there is a significant
interaction between use of CEP, repositioning, and stroke.
+e RESPOND protocol did not require a neurologic
exam by a neurology professional; stroke events were site-
reported and adjudicated by an independent medical re-
viewer, which may have contributed to a lower reported
stroke rate in RESPOND compared with other major TAVR
trials. Similarly, TIA was site-reported and thus may also
have been underidentified. However, RESPOND stroke rates
are consistent with data from the Society of +oracic Sur-
geons/American College of Cardiology Transcatheter Valve
+erapy (STS/ACC TVT) Registry, in which all site-reported
stroke/TIA events were adjudicated by a board-certified
cardiologist (in-hospital stroke rate: 2.0%; 30-day stroke
rate: 2.8%). [23] Finally, patients in RESPOND were not
evaluated for subclinical (silent) ischemic lesions or neu-
rocognitive deterioration, thus the potential effect of such
events in the study population is unknown.
+e currently enrolling PROTECTED TAVR study
(Stroke PROTECTion with SEntinel during Transcatheter
Aortic Valve Replacement; NCT04149535) compares the
72-hour stroke rate in patients undergoing TAVR with or
without the Sentinel dual-filter cerebral protection system.
+is large study (initial enrolment is set at 3000 patients)
will incorporate a formal neurology consult in all patients
where stroke is suspected and should provide important
insights into the impact of CEP on the risk of periproce-
dural stroke.
5. Conclusions
Results from RESPOND suggest that the selective use of a
CEP device for TAVR patients treated with the mechanically
expanded Lotus was associated with a nonsignificant lower
risk for stroke within 72 hours. +e use of the repositioning
feature of the Lotus Valve did not increase the stroke risk. In
future studies, particularly as TAVR is extended to a broader
population, it will be important to evaluate the cognitive
function through a more formal neurological assessment.
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